Literature DB >> 7934096

Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass.

B Frering1, I Philip, M Dehoux, C Rolland, J M Langlois, J M Desmonts.   

Abstract

To determine the cytokine release during normothermic cardiopulmonary bypass, we have measured plasmatic levels of tumor necrosis factor-alpha and interleukins-1 beta, 6, and 8 in 10 patients during the first 24 hours after the start of bypass. Arterial blood samples were collected at intervals before, during, and after bypass. Interleukin-1 beta was not detectable in the plasma, and traces of tumor necrosis factor-alpha were detected in only three patients at times independent of the cardiopulmonary bypass procedure. Circulating endotoxin remained undetectable. Plasma interleukin-6 and interleukin-8 rose significantly from 2 until 24 hours after the start of bypass (p < 0.05) and peaked respectively at 4 and 2 hours after the beginning of bypass (interleukin-6, 268.1 +/- 131.43 pg/ml; interleukin-8, 370 +/- 420 pg/ml; mean peak +/- standard deviation). Peak values of interleukin-6 and interleukin-8 were correlated neither with the duration of aortic crossclamping or the bypass procedure nor with the hemodynamic parameters recorded at the same times. This study shows that normothermic cardiopulmonary bypass does not induce systemic release of tumor necrosis factor-alpha and interleukin-1 beta. A local production of these cytokines cannot be excluded, because interleukin-6 and interleukin-8 are produced by stimulated macrophages and monocytes in response to tumor necrosis factor-alpha and interleukin-1 beta. Our results, at normothermia, show a similar pattern of interleukin-6 and interleukin-8 release when compared with release during hypothermic cardiopulmonary bypass. Interleukin-8, an important chemotactic neutrophil factor, might play a role in reperfusion injuries observed in lungs and heart after cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7934096

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  15 in total

1.  Granulocyte elastase release and pulmonary hemodynamics in patients with mitral valvular disease.

Authors:  Hidenori Gohra; Akihito Mikamo; Haruhiko Okada; Kimikazu Hamano; Nobuya Zempo; Kensuke Esato
Journal:  World J Surg       Date:  2002-04-15       Impact factor: 3.352

2.  Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.

Authors:  T Ozawa; K Yoshihara; N Koyama; S Yamazaki; Y Takanashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-12

3.  [Safety and indication of open heart surgery without blood transfusion for congenital cardiac defects in infants].

Authors:  T Sakamoto; Y Nagase; H Watanabe; M Shibairi; K Utsumi; H Nakano; N Kosai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

Review 4.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

5.  Role of ACE I/D gene polymorphisms on the effect of ramipril in inflammatory response and myocardial injury in patients undergoing coronary artery bypass grafts.

Authors:  Meral Urhan Küçük; Nehir Sucu; Seyhan Şahan Firat; Barlas Naim Aytaçoğlu; Özden Vezir; Caner Bozali; Necmiye Canacankatan; Seval Kul; Bahar Tunçtan
Journal:  Eur J Clin Pharmacol       Date:  2014-09-27       Impact factor: 2.953

Review 6.  Interactions between cytokines and neurohormonal systems in the failing heart.

Authors:  H Kan; M S Finkel
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 7.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

8.  Perioperative serum levels of tumour-necrosis-factor alpha (TNF-alpha), IL-1 beta, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution.

Authors:  A Roth-Isigkeit; T V Borstel; M Seyfarth; P Schmucker
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

9.  Minimal cardiopulmonary bypass attenuates neutrophil activation and cytokine release in coronary artery bypass grafting.

Authors:  Toshihiro Ohata; Masataka Mitsuno; Mitsuhiro Yamamura; Hiroe Tanaka; Yasuhiko Kobayashi; Masaaki Ryomoto; Yoshiteru Yoshioka; Yuji Miyamoto
Journal:  J Artif Organs       Date:  2007-06-20       Impact factor: 1.731

Review 10.  Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review.

Authors:  Catherine Morgan; Michael Zappitelli; Peter Gill
Journal:  Crit Care       Date:  2009-10-20       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.